The Purdue Pharma Documents: What the Sackler Family Actually Knew

On a February morning in 2001, less than five years after OxyContin went on sale, a man named Richard Sackler sat at a keyboard and wrote a sentence that would eventually be read aloud in courtrooms and quoted in headlines around the world. Reports of abuse and overdose were mounting; the press was beginning to circle. Sackler, then the president of Purdue Pharma, wrote to colleagues about how to manage the problem. “We have to hammer on the abusers in every way possible,” he wrote. “They are the culprits and the problem. They are reckless criminals.” For years that email sat in a company server, privileged and unseen. This is the story of how thousands of pages like it were prised out of a private company’s files — and of the gap between what those documents actually prove and what the public came to believe they proved.

A family that stayed behind the curtain

Purdue Pharma was privately held, which is the first thing to understand. Unlike a public corporation, it filed no detailed annual reports to shareholders, held no open earnings calls, faced no activist investors reading its post. The Sackler family owned it through a web of trusts and holding companies, and for most of OxyContin’s life the family name was far better known for philanthropy than for pharmaceuticals. The museum wings and university buildings carried the name; the pill bottles did not.

Two brothers largely built the fortune that made the third famous. Arthur Sackler, a psychiatrist and pioneering medical advertiser, made his name and much of his early money in pharmaceutical marketing decades before OxyContin existed; he died in 1987, nearly a decade before the drug launched, and his branch of the family has argued forcefully that they had no part in it and had sold their share of Purdue. His brothers Mortimer and Raymond, and Raymond’s son Richard, ran the company through the OxyContin years. This distinction — which Sacklers, which years — is exactly the kind of thing that gets flattened when a family becomes a symbol, and it matters for anyone who wants to be accurate rather than merely angry.

What the family knew, and when, was for a long time a matter of inference and rumour. The company had admitted criminal misbranding in 2007, but that plea was made by the corporate entity; the individuals who ran it were shielded behind it. The interesting knowledge — what the owners had personally seen, said and directed — remained locked inside privileged files.

How the files came out

The documents did not surface because the company chose transparency. They came out through the slow, grinding machinery of litigation, and it is worth understanding that machinery, because it is the only reason any of this is on the record.

By the mid-2010s, hundreds of American states, counties, cities and Native American tribes had sued Purdue and other opioid manufacturers and distributors, seeking to recover the public costs of the epidemic. Litigation of that scale generates discovery — the compelled disclosure of internal records — and it generates depositions, sworn testimony taken under oath. The Commonwealth of Massachusetts, under Attorney General Maura Healey, filed a complaint in 2018 that named individual Sacklers as defendants and quoted extensively from internal records; when the state fought to unseal the fuller version, a redacted wall began to come down. Other states followed. Journalists, notably at outlets that had spent years on the story, obtained deposition transcripts and internal emails. Then, in 2019, Purdue filed for Chapter 11 bankruptcy, and the bankruptcy court became a vast repository into which millions of pages were eventually deposited and, in stages, made public.

The bankruptcy is a crucial and underappreciated part of the mechanism. It was, among other things, a legal strategy — a way to consolidate the tidal wave of lawsuits into a single proceeding and negotiate a global settlement. But it also had the side effect of forcing an accounting. To resolve the claims, the court needed to know where the money had gone, and auditors reconstructed the flows: over the years, the family had drawn roughly ten billion dollars out of Purdue, a substantial portion of it after the litigation risk was already clear.

The settlement that eventually emerged became its own long argument about accountability. An early deal that would have granted members of the family sweeping legal immunity from future opioid claims — in exchange for a multi-billion-dollar contribution, while they admitted no wrongdoing — was challenged all the way to the United States Supreme Court, which in 2024 struck it down, ruling that a bankruptcy court could not shield the Sacklers, who had not themselves filed for bankruptcy, from lawsuits in that way. The decision sent the parties back to negotiate, and it turned on a point that captures the whole affair: the family wanted the finality of a bankruptcy without having gone bankrupt, the release of guilt without the admission of it. The documents that made the case against them existed only because the litigation kept refusing to close on those terms.

What the documents actually show

So what is in them? The honest answer is that they are damning in a specific, granular way that is more disturbing than any single sensational quote.

They show a family closely involved in the commercial strategy, pressing for growth. In the launch period, Richard Sackler’s own words, later quoted in filings, described the ambition for the launch to be met with “a blizzard of prescriptions that will bury the competition”. They show the “hammer on the abusers” framing — an owner treating the people becoming addicted to his product as the source of the problem rather than a signal of it. They show the family being briefed, over years, on abuse and diversion, and continuing to press sales. In a 2001 message, when a colleague worried about the mounting deaths, Richard Sackler’s reply reframed the issue as one of public perception and abuser culpability rather than product design.

They show, later, the family exploring how to extract value even as the reckoning approached — including a plan, discussed internally under the name Project Tango, to have Purdue also profit from the addiction-treatment and overdose-reversal market. A company that had helped drive dependence studying whether to sell the remedy for it is the kind of detail that needs no embellishment.

They also show a pattern of blame that ran consistently in one direction. Faced with the mounting evidence of abuse, the internal framing repeatedly located the fault in the patients rather than the product — the drug was safe, the argument went, and any harm came from the criminal choices of people misusing it. That framing is documented across years of communications, and it matters because it describes a settled corporate posture, held over years, a lens through which every new death was filtered. A company that has decided in advance that the problem is its customers rather than its chemistry will keep selling for a very long time, because there is always another abuser to blame.

And they show the money moving. The reconstructed flows established that the family transferred billions out of the company in the years when its legal exposure was becoming unmistakable, a pattern that any prosecutor recognises and that shaped the entire settlement fight.

That is the kernel, and it is solid. The owners were not distant beneficiaries who learned of the harm from the newspapers. They were engaged, informed and driving.

Where belief runs past the record

Now the fork, and it cuts in a direction that surprises people who assume the documents can only understate the guilt.

Because the phrase “the documents show” acquired such authority, almost anything unflattering came to be attributed to them, and some of it will not survive a careful reading. The word “confession” was thrown around; there is no confession in these files of the modern sense — no email in which a Sackler writes that they know the drug is uniquely dangerous and intend to sell it anyway. What the documents show is something legally and morally serious but more diffuse: sustained commercial pressure, a persistent refusal to treat abuse as a product problem, and self-interested framing. That is culpability. It is not the cinematic smoking gun that the shorthand “the Sacklers knew” implies to most listeners.

The single most-quoted lines — “hammer on the abusers”, “blizzard of prescriptions”, “reckless criminals” — are real, and Richard Sackler wrote or received them. But they have been passed around so often, detached from their threads, that they have taken on the character of folklore: a fixed liturgy of villainy recited without the surrounding context that would let a reader weigh them. Some quotes attributed to individual Sacklers in the general online churn are misattributed, compressed, or lifted from the company’s marketing rather than the owners’ mouths. The care that the actual filings took to source each line is precisely the care that evaporates once the story leaves the courtroom.

There is also the matter of the other Sacklers. The steady public usage “the Sacklers” sweeps together the branch that ran the company during the OxyContin years and the branch descended from Arthur, who died before the drug existed and whose heirs have consistently and, on the documentary record, credibly argued they had no role in it. A name on a museum wall is a poor guide to who signed which memo. To insist otherwise is to convict people of a surname.

Why the documents matter more than the myth

It would be easy to treat this as a cautionary tale about exaggeration and leave it there. That would miss the more important thing, which is why the documents came out at all and why that is rarer than it should be.

Almost everything the public knows about the Sacklers’ private conduct exists because an adversarial legal process compelled it into daylight — because attorneys general refused to accept sealed settlements, because a bankruptcy court insisted on tracing the money, because journalists read ten thousand pages of deposition transcript. None of it was volunteered. A privately held company, owned through trusts, briefing its owners in privileged emails, is close to a perfect machine for keeping knowledge private. The only reason the machine failed is that the harm grew so vast that the full weight of American state litigation was brought against it, and even then it took two decades, and even then the family kept most of the money and admitted no personal wrongdoing.

The instinct to embellish — to turn granular culpability into a cinematic confession, to make every Sackler equally guilty, to treat every disputed quote as gospel — comes from the same place as the grief that drove the simpler telling of the crisis itself. When the documented truth is this bad and the consequences to the people responsible are this small, the mind wants the truth to be even worse, because worse might finally be commensurate with the harm. The disappointment is not that the Sacklers were innocent. It is that the real documents, read carefully, describe something the law was never quite built to punish. There was no conspiracy hidden in the dark; there was a family that watched a catastrophe unfold in its own quarterly reports and kept pressing for growth. Understanding that is more useful, and harder to live with, than any single email read aloud in court.